Last reviewed · How we verify
Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer: A Randomized, Controlled, Multicenter Phase II Clinical Trial
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer
Details
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 80 |
| Start date | 2020-01-01 |
| Completion | 2022-01 |
Conditions
- Biliary Tract Cancer
Interventions
- Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
- Gemcitabine Plus(+)Cisplatin
Primary outcomes
- 12 months OS rate — 360 days
The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months
Countries
China